Barzolvolimab

DB18934InvestigationalProtein Based Therapies

Barzolvolimab is under investigation in clinical trial NCT06455202 (A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)).

Mechanism: Pharmacologically active on Mast/stem cell growth factor receptor Kit
Curator reviewed
Also known as: Immunoglobulin G1 [233-alanine,234-glutamine,251-tyrosine,253-threonine,255-glutamic acid,321-glutamine,de-C-terminal-lysine], anti-(human receptor tyrosine kinase KIT extracellular domain) (human-Mus musculus monoclonal CDX-0159 γ1-chain), disulfide wi
Code names: CDX-0159

Resolves to

Compound

UNII4B77GX0NA3CAS2438203-51-9

Targets

P10721KIT

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

12Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Barzolvolimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account